These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19657768)

  • 1. Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?
    Lippi G; Montagnana M; Guidi GC; Plebani M
    Ann Med; 2009; 41(7):480-9. PubMed ID: 19657768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early diagnosis of prostate cancer using free/total prostate-specific antigen ratio with population-based screening data].
    Zhang L; Ji G; Li X; Wang W; Gao H; Pan Y; Wang H; Masaaki K; Zhao X
    Zhonghua Nan Ke Xue; 2004 Aug; 10(8):582-5. PubMed ID: 15362518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Anup P
    BJU Int; 2006 May; 97(5):1039-42. PubMed ID: 16643488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels.
    Pelzer AE; Volgger H; Bektic J; Berger AP; Rehder P; Bartsch G; Horninger W
    BJU Int; 2005 Nov; 96(7):995-8. PubMed ID: 16225515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
    Su HW; Li Y; Xu P
    Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive properties of serum-prostate-specific antigen testing in a community-based setting.
    Jacobsen SJ; Bergstralh EJ; Guess HA; Katusic SK; Klee GG; Oesterling JE; Lieber MM
    Arch Intern Med; 1996 Nov; 156(21):2462-8. PubMed ID: 8944739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
    Kell JS
    Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
    Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
    J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    Rowe EW; Laniado ME; Walker MM; Patel A
    BJU Int; 2005 Jun; 95(9):1249-52. PubMed ID: 15892810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men.
    Capitanio U; Perrotte P; Hutterer GC; Suardi N; Jeldres C; Shariat SF; Duclos A; Arjane P; Montorsi F; Karakiewicz PI
    Int J Urol; 2009 Jan; 16(1):91-5. PubMed ID: 19054167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer. When to offer screening in the primary care setting.
    Gambert SR
    Geriatrics; 2001 Jan; 56(1):22-6, 29-31. PubMed ID: 11196336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
    Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
    Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population.
    Amirrasouli H; Kazerouni F; Sanadizade M; Sanadizade J; Kamalian N; Jalali M; Rahbar K; Karimi K
    Urol J; 2010 Jun; 7(2):99-104. PubMed ID: 20535696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.